# EDGAR Filing Document

**Accession Number:** 0001606498
**File Stem:** 0001606498-25-000123
**Filing Date:** 2025-9
**Character Count:** 9670
**Document Hash:** f2d488a80cc12caaaa17c64dfc43f0f6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001606498-25-000123.hdr.sgml**: 20250915

**ACCESSION NUMBER**: 0001606498-25-000123

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20250915

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20250915

**DATE AS OF CHANGE**: 20250915

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** AVANOS MEDICAL, INC.
- **CENTRAL INDEX KEY:** 0001606498
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 464987888
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36440
- **FILM NUMBER:** 251313157

**BUSINESS ADDRESS:**
- **STREET 1:** 5405 WINDWARD PARKWAY
- **STREET 2:** SUITE 100 SOUTH
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30004
- **BUSINESS PHONE:** 844-428-2667

**MAIL ADDRESS:**
- **STREET 1:** 5405 WINDWARD PARKWAY
- **STREET 2:** SUITE 100 SOUTH
- **CITY:** ALPHARETTA
- **STATE:** GA
- **ZIP:** 30004

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Avanos Medical, Inc.
- **DATE OF NAME CHANGE:** 20180702

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Halyard Health, Inc.
- **DATE OF NAME CHANGE:** 20140424

?xml version='1.0' encoding='ASCII'? avns-20250915

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

**FORM 8-K** 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **September 15, 2025** 

![avanoslogo.jpg](avns-20250915_g1.jpg)

**AVANOS MEDICAL, INC.** 

(Exact name of registrant as specified in its charter)

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| **Delaware** | **Delaware** | **001-36440** | **001-36440** | | **46-4987888** |
| (State or other jurisdiction of incorporation) | (State or other jurisdiction of incorporation) | (Commission File Number) | (Commission File Number) | | (I.R.S. Employer Identification No.) |
| | **5405 Windward Parkway** | **5405 Windward Parkway** | **5405 Windward Parkway** | **5405 Windward Parkway** | **5405 Windward Parkway** |
| | **Suite 100 South** | **Suite 100 South** | **Suite 100 South** | **Suite 100 South** | **Suite 100 South** |
| | **Alpharetta,** | **Alpharetta,** | **Georgia** | **30004** | **30004** |
| | (Address of principal executive offices) | (Address of principal executive offices) | (Address of principal executive offices) | (Zip code) | (Zip code) |

---

**Registrant's telephone number, including area code: (844) 428-2667**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| **Common Stock - $0.01 Par Value** | **AVNS** | **New York Stock Exchange** |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure**

On September 15, 2025, Avanos Medical, Inc. (the "Company") issued a press release announcing that the Company has acquired Nexus Medical, LLC. A copy of such press release is attached as Exhibit 99.1 hereto and is incorporated by reference herein in its entirety.

The information in Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in Item 7.01 of this Current Report shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, except as otherwise expressly stated in such filing.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Exhibits.

&nbsp;&nbsp;&nbsp;&nbsp;The following exhibits are filed with this Current Report on Form 8-K:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| <u>[99.1](avnsform8k_09152025xex991.htm)</u> | <u>[Press release issued by Avanos Medical, Inc. on September 15, 2025](avnsform8k_09152025xex991.htm)</u> |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document) |

---

------

**<u>SIGNATURE</u>**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

&nbsp;&nbsp;&nbsp;&nbsp;

---

| | | | |
|:---|:---|:---|:---|
| | | AVANOS MEDICAL, INC. | AVANOS MEDICAL, INC. |
| Date: | September 15, 2025 | By: | /s/ Mojirade James |
|  |  |  | Mojirade James<br>Senior Vice President and General Counsel |

---

## Exhibit 99.1

**Avanos Medical Acquires Nexus Medical to Strengthen Nutrition and Medication Delivery in Critical Care** 

**ALPHARETTA, Ga., Sept. 15, 2025 /PRNewswire/** — Avanos Medical, Inc. (NYSE: AVNS), a leading medical technology company, today announced the acquisition of Nexus Medical, LLC, a privately held medical device company based in Lenexa, Kansas.

Nexus is the maker of the proprietary TKO<sup>®</sup> anti-reflux needleless connector technology, designed to support safer, more consistent nutrition and medication delivery in high-acuity settings, including Neonatal and Pediatric Intensive Care Units (NICUs and PICUs).

The acquisition adds complementary technology to Avanos' Specialty Nutrition Systems business and reinforces the company's focus on safe, reliable therapy delivery for the neonatal patient population.

"This acquisition is a clear extension of our strategy to deliver smarter, safer solutions across the critical care spectrum," said Dave Pacitti, Avanos chief executive officer. "We are proud to add the Nexus TKO<sup>®</sup> technology and the full breadth of Nexus' offerings to our portfolio as we continue investing in meaningful innovation that helps clinicians provide consistent care and improve outcomes for patients who need it most."

The TKO<sup>®</sup> needleless connector features a patented, pressure-activated tri-seal silicone valve that minimizes blood reflux – a known contributor to catheter occlusions, therapy delays, and infection risk during IV-based nutrition and medication delivery.\*

"Nexus TKO<sup>®</sup> fits naturally into our Specialty Nutrition Systems business and is expected to deliver immediate value in NICU and PICU care," said Kerr Holbrook, Avanos' chief commercial officer. "It's a practical, trusted solution that helps clinicians reduce disruptions and deliver therapy with greater consistency and ease."

Avanos financed the acquisition with available cash. The company expects the acquisition to be immediately accretive to both revenue growth and earnings per share.

**About Avanos Medical**

Avanos Medical (NYSE: AVNS) is a medical technology company focused on delivering clinically superior medical device solutions that help patients get back to the things that matter. Headquartered in Alpharetta, Georgia, Avanos is committed to addressing some of today's most important healthcare needs, including providing a vital lifeline for nutrition to patients from hospital to home, and reducing the use of opioids while helping patients move from surgery to recovery. Avanos develops, manufactures and markets its recognized

------

brands globally and holds leading market positions in multiple product categories. For more information, visit <u>www.avanos.com</u> and follow Avanos Medical on X (@AvanosMedical), LinkedIn and Facebook.

**About Nexus Medical**<br>Founded in 2001, Nexus Medical invented the anti-reflux category in needleless connectors to solve the unintended consequences of blood reflux in IV catheters, including intraluminal thrombotic occlusions, catheter failure, and infections. As the most studied needleless connector on the market, the Nexus TKO<sup>®</sup> anti-reflux technology is an evidence-based way to simplify the complexity of IV therapy and improve patient safety. For more information, call (913) 451-2234 or visit <u>www.nexusmedical.com</u>.

**\*CLAIM ON FILE**

**SOURCE**: Avanos Medical, Inc.

**For further information:** Katrine Kubis, Vice President, Corporate Communications, Avanos Medical, Inc., <u>CorporateCommunications@Avanos.com</u> 

<br>